FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55403
News■ Mixed
Medicare Advantage plans will be cheaper next year. Here’s the new cost.
KINDNews
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 15:16 UTC
LAST UPDATE2026-09-29 15:16 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Cheaper Medicare Advantage premiums may lift enrollment but pressure insurer margins.
MA pricing shifts risk from seniors to insurers
CATALYST TO WATCH
Open enrollment starting October 15
MAIN RISK
Margin compression for MA-heavy insurers
FULL DISPATCH
Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Impruvon to Streamline Missouri's Statewide Medication Management & HRST Automation2026-09-29 15:30 UTC
Impruvon to Streamline Missouri's Statewide Medication Management & HRST Automation2026-09-29 15:30 UTC
→CORRELATIONshares Healthcare
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.